Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.30 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15042917 | 0.85 | HTR2A (0.42) | HTR2AKDM1AMEN1KMT2ALMNA | |
| SCHEMBL15042872 | 0.82 | HTR2A (0.34) | HTR2AKDM1ASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL19485911 | 0.80 | HTR2A (0.37) | HTR2AKDM1ASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL19565413 | 0.76 | KDM1A (0.47) | HTR2AKDM1ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL15042911 | 0.73 | DRD1 (0.39) | KDM4EMEN1KMT2A | |
| SCHEMBL15042871 | 0.73 | HTR2A (0.44) | HTR2AKDM1ASMN1; SMN2MAPK1CASP6 | |
| SCHEMBL15042875 | 0.71 | DRD5 (0.43) | KDM4EMEN1KMT2A | |
| SCHEMBL15042925 | 0.70 | MAOA (0.39) | SMN1; SMN2KDM4EMEN1KMT2AGAA | |
| SCHEMBL19485964 | 0.67 | HTR2A (0.37) | HTR2AKDM1ASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL15042823 | 0.67 | HSD17B10 (0.37) | HTR2AKDM1AKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796705-B2 | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170008879-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | SCHERING CORPORATION | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | HAVCR2, ELOC, ZC3HAV1 | HTR2A 2505/4885KDM1A 2392/4885SMN1; SMN2 1324/4885 |
| US-20170008879-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | ZC3HAV1, HAVCR2, ZC3HAV1L | HTR2A 4215/4885KDM1A 3420/4885SMN1; SMN2 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.